ClinicalTrials.gg
Not yet recruitingNCT07081776OPTIMUS-MASKUpdated Jul 23, 2025

Evaluation of the Effects on Carbon Dioxide (paCO2) of a New Oronasal Mask in Patients With Severe COPD Exacerbation Requiring Non-Invasive Mechanical Ventilation

An interventional study of OptiNIV and Visairo in COPD and Respiratory Acidosis, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Pulmonary Disease, Chronic Obstructive by IRCCS Azienda Ospedaliero-Universitaria di Bologna — 4 open to participants now, 4 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Planned enrollment
5th of 10
21 · median 21
Started
2025
with 2 others
No phase
5 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Pulmonary Disease, Chronic Obstructive by IRCCS Azienda Ospedaliero-Universitaria di Bologna, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

4 of the 12 studies in Pulmonary Disease, Chronic Obstructive by IRCCS Azienda Ospedaliero-Universitaria di Bologna are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pulmonary Disease, Chronic Obstructive by IRCCS Azienda Ospedaliero-Universitaria di Bologna, or all of them as a file.
02

Study summary

This single-center, crossover study aims to investigate the effects of the new OptiNIV oronasal mask used during NIV in COPD patients with respiratory acidosis following an exacerbation. The goal is to evaluate whether the clinical benefits, in terms of reducing PaCO2 levels, are greater with the new mask compared to a traditional one (Visairo Mask).

Read the detailed description

Non-invasive ventilation (NIV) is considered the gold standard treatment, in combination with medical therapy, for patients with respiratory acidosis secondary to Chronic Obstructive Pulmonary Disease (COPD). The choice of interface is a key factor in the success of NIV. A new oronasal mask, designed to improve CO2 washout (OptiNIV, Fisher \& Paykel Healthcare, New Zealand), has recently been introduced to the market. Experimental data show that this interface, with a unique design separating airflow between the patient's mouth and nose, enhances gas flow at the end of expiration towards the oropharynx and subsequently out through the nostrils. This design facilitates the removal of CO2-rich air from the upper airways via dedicated ventilation ports located at the front of the mask, thereby optimizing CO2 clearance and dead space ventilation, which improves ventilatory efficiency.

This single-center, crossover study aims to investigate the effects of a new oronasal mask used during non-invasive ventilation (NIV) in COPD patients experiencing respiratory acidosis following an exacerbation. The objective is to assess whether the clinical benefits, specifically the reduction of PaCO₂ levels, are greater with the new mask compared to a traditional one. To minimize confounding factors affecting carbon dioxide washout, the new mask (OptiNIV, Fisher \& Paykel Healthcare, New Zealand) will be compared to a mask of similar size, internal volume, and technical features (Visairo, Fisher \& Paykel Healthcare, New Zealand), differing only in the presence of a separated airflow between the mouth and nose. This study holds significant clinical relevance, as no data are currently available on the use of the OptiNIV mask in patients with acute respiratory acidosis secondary to COPD exacerbation. The results could lead to optimized carbon dioxide clearance and improved ventilatory efficiency in managing patients with severe COPD exacerbations.

The study population consists of patients with respiratory acidosis secondary to COPD exacerbation who require non-invasive ventilation (NIV) and are admitted to the Respiratory and Critical Care Unit at the IRCCS AOU of Bologna, Policlinico S. Orsola. Patients meeting eligibility criteria will be randomly assigned (1:1) to two consecutive 60-minute NIV sessions using a traditional oronasal mask (Visairo) and an optimized mask (OptiNIV), following a crossover design. The sequence of mask use will be randomly assigned by the randomization list. NIV will be delivered with the same ventilator (ASTRAL 150 - ResMed Europe) using a single-limb circuit and pressure support mode, adjusting FiO₂ to maintain SpO₂ between 88-92%. Ventilator settings (IPAP, EPAP, triggers, rise time, Ti min, Ti max) will be set according to clinical practice but kept constant between sessions.

A 30-minute washout period with Venturi mask oxygen therapy will separate the two sessions, aiming to maintain SpO₂ between 88-92%. At the end of the washout, transcutaneous CO₂ (PtCO₂) will be measured; if this value is within ±2 mmHg of baseline, patient will proceed to the second session; otherwise, the washout will be extended up to 60 minutes. Including the washout, the total study duration per patient will not exceed 3 hours.

03

Conditions studied

  • COPD
  • Respiratory Acidosis

Keywords

  • COPD
  • NIV
  • Oronasal Mask
  • PaCO2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • obtained
  • Patients with and acute hypoxemic-hypercapnic respiratory failure (pH \< 7.35, PaO₂ \< 60 mmHg, PaCO₂ > 45 mmHg) requiring non-invasive mechanical ventilation.

Exclusion criteria

Exclusion Criteria:

  • ≥ 30 kg/m²
  • Obstructive sleep apnea syndrome
  • Neuromuscular diseases or chest wall pathologies
  • Need for intubation and invasive mechanical ventilation during exacerbation
  • Use of home non-invasive mechanical ventilation or CPAP
  • for NIV
  • Cognitive disorders that may interfere with adherence to treatments
  • Patients with active and unstable coronary artery disease
  • Previous esophageal surgery, known esophageal stenosis, or any other condition that could put the patient at risk during the placement of the respiratory mechanics probe
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    OptiNIV

    Patients will undergo treatment with the OptiNIV Mask

    Device: OptiNIV

  • Active comparator
    Visairo

    Patients will undergo treatment with Visairo Mask

    Device: Visairo

Interventions

  • DeviceOptiNIV

    Patients assigned to the "OptiNIV" group will be submitted to two consecutive 60-minute sessions. In the first session, they will receive NIV with an "optimized" mask (OptiNIV) and in the second session they will receive NIV with a traditional" oronasal mask (Visairo). The study will follow a crossover design, meaning each patient will undergo both sessions, In both sessions, NIV will be delivered using the same ventilator (ASTRAL 150 - ResMed Europe). Ventilator settings will be set to ensure the most effective ventilation and the best comfort for each patient. However, these settings must remain unchanged during the two sessions. A 30-minute washout period is planned between the sessions, during which patients will receive traditional oxygen therapy through a Venturi mask. The 30 min wash-out periodod can be extended until PtCO₂ returns within ±2 mmHg of baseline or until 60 minutes have passed. The maximum total treatment time for each patient will be approximately 3 hours.

  • DeviceVisairo

    Patients assigned to the "Visairo" group will be submitted to two consecutive 60-minute sessions. In the first session, they will receive NIV with a "traditional" oronasal mask (Visairo) and in the second session they will receive NIV with an "optimized" mask (OptiNIV). The study will follow a crossover design, meaning each patient will undergo both sessions. In both sessions, NIV will be delivered using the same ventilator (ASTRAL 150 - ResMed Europe). Ventilator settings will be set to ensure the most effective ventilation and the best comfort for each patient. However, these settings must remain unchanged during the two sessions. A 30-minute washout period is planned between the sessions, during which patients will receive traditional oxygen therapy through a Venturi mask. The 30 min wash-out periodod can be extended until PtCO₂ returns within ±2 mmHg of baseline or until 60 minutes have passed. The maximum total treatment time for each patient will be approximately 3 hours.

06

What researchers measure

Primary outcomes

  1. Evaluation of the effects of the OptiNIV oronasal mask on partial pressure of carbon dioxide (PaCO₂) levels in patients with severe COPD exacerbation requiring treatment with non-invasive mechanical ventilation.

    Measured through arterial blood gas analysis. Unit of measurement: mmHg

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

Secondary outcomes

  1. Evaluation of changes in paO2

    It will be measured through arterial blood gas analysis Unit of measuremet: mmHg

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  2. Evaluation of changes in HCO3-

    It will be measured through arterial blood gas analysis

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  3. Evaluation of changes in pH

    It will be measured through arterial blood gas analysis

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  4. Evaluation of changes in PaO₂/FiO₂

    It will be measured through arterial blood gas analysis

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  5. Evaluation of changes in blood pressure

    It will be measured using a sphygmomanometer Unit of measuremet: mmHg

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  6. Evaluation of changes in the heart rate

    It will be measured using a pulsoximeter Unit of measuremet: bpm

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  7. Evaluation of changes in the respiratory pattern

    It will be measured using the Minute Ventilation data and Respiratory Rate data obtained through a respiratory inductance plethysmography

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  8. Evaluation of changes in the Ventilatory Ratio

    It will be measured using the formula VR = (minute ventilation \[ml/min\] × PaCO₂) / (predicted weight \[kg\] × 100 × 37.5).

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  9. Evaluation of changes in the end-tidal carbon dioxide (etCO₂)

    It will be measured using a capnograph

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  10. Evaluation of changes in the esophageal pressure swing

    It will be measured via a nasogastric tube with an esophageal balloon.

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  11. Evaluation of changes in the asynchrony index

    It will be measured using the formula: AI = number of asynchronies / RR x 100 and will be measured by downloading the ventilator data at the end of each session

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  12. Evaluation of changes in transcutaneous SpO₂ %

    Will be measured via transcutaneous monitoring of SpO₂ that will be performed using a dedicated device that will record data for the entire duration of the study. Data at the end of each session will be compared with the data obtained at the beginning of the session. Unit of measure: %

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  13. Evaluation of changes in transcutaneous TcCO2

    Will be measured via transcutaneous monitoring of TcCO2 that will be performed using a dedicated device that will record data for the entire duration of the study. Data at the end of each session will be compared with the data obtained at the beginning of the session. Unit of measure: mmHg

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  14. Evaluation of dyspnea

    It will be measured using a visual analog scale (VAS) ranging from 0 to 100 where 0 represents minimum dyspnea and 100 represents maximum dyspnea

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  15. Evaluation of the comfort level experienced

    It will be measured using a visual analog scale (VAS) with a score ranging from 0 to 10, where 0 represents maximum comfort and 10 represents maximum discomfort.

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  16. Evaluation of NIV failure

    NIV failure will be measured as the need for invasive mechanical ventilation (IMV)

    Time frame: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).

  17. Occurrance of adverse events

    will be measured by recording any complications (skin irritation or ulcers, gastric distension, pneumothorax, hypotension, conjunctivitis, claustrophobia, aspiration) that occur during sessions with the two interfaces

    Time frame: T1 ( + 1 hour) and at T3 (+ 3 hours).

07

Study locations

1 site
  • U.O Pneumologia e Terapia Intensiva Respiratora, IRCCS AOU di Bologna
    Bologna, Bologna 40138, Italy
08

References and documents

Publications

  • Piquilloud L, Olivier PY, Richard JC, Thepot-Seegers V, Brochard L, Mercat A, Beloncle F. High flow nasal cannula improves breathing efficiency and ventilatory ratio in COPD patients recovering from an exacerbation. J Crit Care. 2022 Jun;69:154023. doi: 10.1016/j.jcrc.2022.154023. Epub 2022 Mar 26. PubMed 35349909 ↗
  • Charususin N, Dacha S, Gosselink R, Decramer M, Von Leupoldt A, Reijnders T, Louvaris Z, Langer D. Respiratory muscle function and exercise limitation in patients with chronic obstructive pulmonary disease: a review. Expert Rev Respir Med. 2018 Jan;12(1):67-79. doi: 10.1080/17476348.2018.1398084. Epub 2017 Nov 6. PubMed 29072087 ↗
  • Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, Navalesi P Members Of The Steering Committee, Antonelli M, Brozek J, Conti G, Ferrer M, Guntupalli K, Jaber S, Keenan S, Mancebo J, Mehta S, Raoof S Members Of The Task Force. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017 Aug 31;50(2):1602426. doi: 10.1183/13993003.02426-2016. Print 2017 Aug. PubMed 28860265 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Oct 2026, 14 months later.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 14 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
Jul 23, 2025
StartEst.
Aug 2025
Primary completionEst.
Oct 2026
CompletionEst.
Jun 2027
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07081776
Responsible party
dr. Stefano Nava (Prof., IRCCS Azienda Ospedaliero-Universitaria di Bologna) — Principal investigator
First posted
Jul 23, 2025
Start date
Aug 2025 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 23, 2025

Study contacts

Lara Pisani, MD
Contact
lara.pisani@unibo.it
+39 0512143257

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion